Compare ADMA Biologics Inc (ADMA) vs General Motors Company (GM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs General Motors Company — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while General Motors Company trades at $75.72 (market cap $68.55B). The key difference: General Motors Company is far larger — about 32.2× ADMA Biologics Inc's market cap, and General Motors Company pays a 0.95% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | GM | |
|---|---|---|
Market Cap | $2.13B | $68.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $86.38 |
52-Week Low | $7.60 | $48.89 |
Enterprise Value | $2.20B | $171.89B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
General Motors (GM) trades at $76.03, showing minimal daily movement with a 0.04% gain. The stock presents a mixed technical picture with bearish moving averages but oversold RSI conditions. Fundamentally, GM demonstrates strong cash flow generation ($26.9B operating cash flow in 2025) and consistent earnings beats, though profit margins remain thin at 1.38%. Recent news highlights strategic partnerships with Micron Technology and ongoing EV transition challenges.
GM offers value with attractive valuation multiples (P/S: 0.4x, P/B: 1.12x) and analyst consensus pointing to 31% upside potential. However, investors face risks from cyclical auto demand, margin pressure, and high debt levels. The company's scale and cash flow strength provide stability, but execution on EV strategy remains critical for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
